Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?

7 Oct 2020

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) exploit BRCA mutations and DNA damage response (DDR) deficiencies. Inhibition of PARP leads to propagation of single-strand DNA breaks and accumulation of double-strand breaks, which require homologous recombination (HR) repair mechanisms. PARP inhibitors were initially developed as maintenance therapy in patients with sustained complete or partial response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33038760
DOI: 10.1016/j.ebiom.2020.103046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?PMID 33038760Read ↗

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?Semantic proximity Read ↗

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read ↗

PARP Inhibitors in Ovarian CancerSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving StrategiesSemantic proximity Read ↗

A review on mechanisms of resistance to PARP inhibitorsSemantic proximity Read ↗

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancerSemantic proximity Read ↗

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsSemantic proximity Read ↗

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancerSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP inhibitors: Clinical utility and possibilities of overcoming resistanceSemantic proximity Read ↗

PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.